School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Dongzhimen 16 Nanxiao Road, Dongcheng District, Beijing 100700, China.
Biomed Pharmacother. 2019 Dec;120:109442. doi: 10.1016/j.biopha.2019.109442. Epub 2019 Sep 20.
To evaluate whether Xiaoerfupi (XEFP), a traditional Chinese medicine formula, can ameliorate functional dyspepsia (FD) through regulation of the HTR3A and c-FOS.
The FD rat model was established through administration of iodoacetamide (IA) and interval fasting. XEFP group rats received XEFP for 3 weeks. Detection of gastric emptying and gastrin were performed to assess the interventional effect of XEFP. The constituents of XEFP were submitted to BATMAN-TCM, an online bioinformatics analysis tool, to predict the targets related to dyspepsia. Furthermore, the prediction was validated via Western blot assay.
XEFP enhanced gastric emptying of rats (XEFP middle dose vs. FD model: 71.87 ± 15.21% vs. 30.07 ± 12.76%, P < 0.01) and simultaneously increased gastrin in FD rats (XEFP middle dose vs. FD model: 63.61 ± 17.90 vs. 26.14 ± 7.78 pg/ml, P < 0.01). KEGG enrichment analysis revealed that the neuroactive ligand-receptor interaction was successfully enriched (P-value = 2.2E-13, Benjamini = 2.0E-11). Combining different Bioinformatics analysis implied that XEFP regulates HTR3A and c-FOS. Subsequently molecular biological studies confirmed that the expression of HTR3A and c-FOS in the model group was upregulated in rats in comparison with the control group. Furthermore, the expression of HTR3A and c-FOS in the XEFP group (middle dose) compared with the model group was significantly reduced (P < 0.01).
XEFP may ameliorate FD through regulation of the HTR3A and c-FOS.
评价小儿敷脾散（XEFP）是否通过调节 HTR3A 和 c-FOS 来改善功能性消化不良（FD）。
通过碘乙酰胺（IA）和间隔禁食建立 FD 大鼠模型。XEFP 组大鼠给予 XEFP 治疗 3 周。检测胃排空和胃泌素以评估 XEFP 的干预作用。将 XEFP 的成分提交给在线生物信息学分析工具 BATMAN-TCM，以预测与消化不良相关的靶点。此外，通过 Western blot 检测验证预测。
XEFP 增强了大鼠的胃排空（XEFP 中剂量组与 FD 模型组相比：71.87 ± 15.21% vs. 30.07 ± 12.76%，P < 0.01），同时增加了 FD 大鼠的胃泌素（XEFP 中剂量组与 FD 模型组相比：63.61 ± 17.90 vs. 26.14 ± 7.78 pg/ml，P < 0.01）。KEGG 富集分析显示神经活性配体-受体相互作用成功富集（P 值=2.2E-13，Benjamini 值=2.0E-11）。结合不同的生物信息学分析表明，XEFP 调节 HTR3A 和 c-FOS。随后的分子生物学研究证实，与对照组相比，模型组大鼠 HTR3A 和 c-FOS 的表达上调。此外，与模型组相比，XEFP 组（中剂量）大鼠 HTR3A 和 c-FOS 的表达明显降低（P < 0.01）。
XEFP 可能通过调节 HTR3A 和 c-FOS 来改善 FD。
